|  | Cancer | Cancer Treatment

Pancreatic Neuroendocrine Tumor (Islet Cell Cancer) Treatment: Comprehensive Overview

Treatment Overview

Pancreatic neuroendocrine tumors (pNETs, formerly islet cell cancers) are heterogeneous. Treatment is individualized by: tumor grade (Ki-67/mitotic rate), stage, functionality (hormone secretion), somatostatin receptor status, and patient factors.

Surgical Management

Curative Intent (Localized Disease)

  • Enucleation: Small (<2 cm), non-functional, superficial tumors; preserves parenchyma. Robotic/laparoscopic preferred.
  • Distal Pancreatectomy (± Splenectomy): Body/tail tumors. Spleen preservation when possible (immunologic function).
  • Pancreatoduodenectomy (Whipple): Head/uncinate tumors. High morbidity (30-40%); mortality <2% at high-volume centers.
  • Central Pancreatectomy: Neck tumors; preserves head and tail; higher fistula risk.
  • Lymphadenectomy: Standard with resection; prognostic.

Cytoreductive Surgery (Metastatic)

  • >90% debulking improves symptom control (hormonal syndromes) and may prolong survival.
  • Liver-directed: Resection, ablation (RFA/MWA), embolization (TACE/TARE).

Medical Therapies

Somatostatin Analogs (SSAs) – First-Line for Functional/Metastatic

  • Octreotide LAR 30 mg / Lanreotide 120 mg q28 days.
  • Control hormone syndromes (carcinoid, insulinoma, gastrinoma, VIPoma, glucagonoma).
  • Antiproliferative: PROMID/CLARINET trials – PFS benefit in well-differentiated pNETs.

Targeted Therapies

  • Everolimus (mTOR inhibitor): RADIANT-3 trial – PFS 11.0 vs 4.6 months (progressive pNETs).
  • Sunitinib (VEGFR/PDGFR inhibitor): Phase III – PFS 11.4 vs 5.5 months (progressive pNETs).
  • Belzutifan (HIF-2α inhibitor): Approved 2021 for VHL-associated pNETs; trials in sporadic.

Peptide Receptor Radionuclide Therapy (PRRT)

  • 177Lu-DOTATATE (Lutathera®): NETTER-1 trial – unprecedented PFS/OS benefit in SSTR+ GEP-NETs.
  • 4 cycles q8 weeks; renal/hematologic monitoring; amino acid infusion for renal protection.
  • Indication: SSTR+, well-differentiated, progressive pNETs.

Chemotherapy

  • High-Grade (G3, Ki-67 >20%): Platinum/etoposide (small cell) or temozolomide/capecitabine (well-differentiated G3).
  • Well-Differentiated (G1/G2): Temozolomide-based regimens (CAPTEM) – response rates 30-70%.
  • Streptozocin-based (historical): More toxic; limited current use.

Symptom-Specific Management

  • Insulinoma: Diazoxide, SSAs, enucleation/resection.
  • Gastrinoma (Zollinger-Ellison): High-dose PPIs, SSAs, resection.
  • Carcinoid Syndrome: SSAs, telotristat ethyl (tryptophan hydroxylase inhibitor).

Other Modalities

  • Radiation Therapy: Palliative (bone pain, bulky nodes); SBRT for oligometastases.
  • Liver-Directed: TACE, TARE, bland embolization, ablation.
  • Clinical Trials: Immunotherapy (PD-1/PD-L1), novel targeted agents, combination strategies.

Follow-Up

  • Multidisciplinary tumor board essential.
  • Surveillance: CT/MRI q6-12mo (G1/G2), q3-6mo (G3); chromogranin A, specific hormones.
  • Genetic testing: MEN1, VHL, NF1, TSC if indicated.

Cancer Treatment - Related Articles